Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Eco Animal Health sells equine parasite treatment for EUR 1.3m
(Sharecast News) - Eco Animal Health announced the sale of 'ECOmectin Horsepaste' to its manufacturing partner Acme Drugs in Italy on Thursday, for total consideration of €1.3m. The AIM-traded firm said that as part of a strategic move aimed at refining its focus, ECOmectin Horsepaste - a branded equine parasite treatment featuring the active ingredient ivermectin - had been deemed non-core to its operations for some time.
Under the terms of the transaction, Acme acquired all marketing authorisations held by Eco for ECOmectin Horsepaste, along with associated intellectual property, manufacturing and distribution arrangements, and existing inventory.
The marketing authorisations primarily spanned the UK and EU markets.
Additionally, Acme was granted a trademark licence to market and sell the horse paste under the ECOmectin brand.
The total consideration for the transaction amounted to €1.3m, with €0.5m disbursed on the signing of the sale and purchase agreement.
Acme committed to making two further payments of €0.4m each, with the first instalment due 18 months post-completion and the second 36 months thereafter.
Those deferred payments weer backed by a bank guarantee, which was set to be finalised within 45 days.
For the financial year ended 31 March, revenue generated from the business segment totalled £0.81m, compared to £0.99m in 2023.
The Eco Animal Health board saw the transaction as a pivotal step in refining its focus on core species, particularly pigs and poultry, and advancing its innovative pipeline of vaccines and preventatives.
It said the proceeds from the transaction were earmarked for reinvestment in research and development initiatives to bolster new product development efforts.
"The disposal of ECOmectin Horsepaste is in line with our stated intention of focusing on treatments and preventatives in pigs and poultry and this enables us to increase investment in our research and development pipeline," said chief executive officer David Hallas.
"The brand and the broader business is a good fit for Acme Drugs, and we are pleased that the business will be taken forward by a committed owner.
"We continue to look for value accretive opportunities both within our portfolio and outside and for opportunities to reinvest in our research and development pipeline to support future growth."
At 1120 BST, shares in Eco Animal Health Group were down 1.18% at 84p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.